Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.


Background: Individuals with a number of sclerosis spasticity (MSS) and upper limb/hand impairment who are taking 9-delta-tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray (Sativex®) may possibly have difficulty self-administering their medication, possibly limiting adherence and remedy effectiveness. A Class I EU device is offered to help administration of THC:CBD spray. Pre-production testing was undertaken in a patient sample. Procedures: Present customers of THC:CBD spray had been recruited to assessment the instruction leaflet and test the device. Individuals and observing healthcare experts (HCP) completed a objective-created questionnaire which captured user knowledge and HCP opinion. Final results: Fifteen sufferers participated. Imply remedy time with THC:CBD spray was four (variety: .1-six.1) years. 87% of participants ‘always’, ‘often’ or ‘sometimes’ had hand impairment, and 53% reported difficulty administering THC:CBD spray. Participants reported improved application working with the device (73%), with significantly less strength necessary (54%). Most participants (93%) thought of the instruction leaflet to be clear and several (66%) expressed interest in working with the device. Most HCPs (93%) did not foresee any issues in use of the device. Conclusion: The proposed adherence device was valuable to address self-application issues with THC:CBD spray in our sample. Delivering the device to MSS sufferers with upper limb/hand spasticity impairment may possibly restore autonomy and help adherence to THC:CBD spray.


Latest posts